Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II open label, non comparative, non randomized study for the assessment of the efficacy and safety of lenalidomide + adriamycine and low dose dexamethasone combination (RAD) in newly diagnosed, symptomatic multiple myeloma patients who are eligible for high dose therapy and autologous stem cell transplantation.

Next Previous
Trial Profile

A phase II open label, non comparative, non randomized study for the assessment of the efficacy and safety of lenalidomide + adriamycine and low dose dexamethasone combination (RAD) in newly diagnosed, symptomatic multiple myeloma patients who are eligible for high dose therapy and autologous stem cell transplantation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dexamethasone (Primary) ; Doxorubicin (Primary) ; Lenalidomide (Primary) ; Low molecular weight heparins; Zoledronic acid
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms RAD

Most Recent Events

  • 25 Jun 2017 Final results of the Greek Myeloma Study Group, presented at the 22nd Congress of the European Haematology Association
  • 06 Dec 2016 Results (cut off data February 2016, n=45) assessing efficacy of RAD as induction therapy for NDMM patients, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
  • 14 Oct 2016 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top